SCHEMBL25811806

SCHEMBL25811806

CCc1[nH]c2ccc(C(=O)N(C)CCN3CCOCC3)cc2c1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.43
MEN1 O00255 2/20 0.43
PPARG P37231 1/20 0.42
NR2E3 Q9Y5X4 1/20 0.42
NCOR2 Q9Y618 1/20 0.42
TLR9 Q9NR96 2/20 0.42
TLR8 Q9NR97 2/20 0.42
TLR7 Q9NYK1 2/20 0.42
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CHRM3 P20309 1/20 0.42
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
PIK3CD O00329 1/20 0.40
PARP1 P09874 1/20 0.40
CYP19A1 P11511 1/20 0.40
MAPT P10636 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25815032 0.91 KMT2A (0.45) KMT2ATLR9TLR8TLR7ALDH1A1
SCHEMBL25812014 0.90 KMT2A (0.49) KMT2ATLR9TLR8TLR7ALDH1A1
SCHEMBL25814483 0.89 ALDH1A1 (0.53) KMT2AMEN1ALDH1A1KDM4EL3MBTL1
SCHEMBL25811810 0.86 TLR9 (0.48) KMT2AMEN1PPARGNR2E3NCOR2
SCHEMBL25811268 0.81 KMT2A (0.62) KMT2AALDH1A1KDM4EL3MBTL1PARP1
SCHEMBL25811960 0.80 KMT2A (0.47) KMT2AMEN1TLR9TLR8TLR7
SCHEMBL25811720 0.79 KDR (0.49) KMT2AMEN1ALDH1A1KDM4EL3MBTL1
SCHEMBL25811965 0.79 MAPT (0.52) KMT2AMEN1ALDH1A1KDM4EL3MBTL1
SCHEMBL25811987 0.79 KMT2A (0.58) KMT2AMEN1ALDH1A1KDM4EL3MBTL1
SCHEMBL25811801 0.79 KMT2A (0.61) KMT2AMEN1ALDH1A1KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES GALYAN BIO INC (US) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES HTT, HYPK, PARK7 KMT2A 981/4885MEN1 3841/4885PPARG 1793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.